Opendata, web and dolomites

RESOLVE SIGNED

tPA-Nanoconstructs for Treating Acute Ischemic Stroke: a Technical and Commercial Analysis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESOLVE project word cloud

Explore the words cloud of the RESOLVE project. It provides you a very rough idea of what is the project "RESOLVE" about.

20b    thrombolysis    polymeric    diminish    companies    worldwide       thrombolytic    limitations    stability    discoidal    sale    designed    deaths    ischemic    nano    emotional    induces    drug    secured    considerable    agents    models    clinically    complications    acute    dissolution    profiles    estimate    clots    blood    vessels    economic    small    clot    medical    cerebral    causing    damage    indirect    excretion    tech    lasting    dpns    death    whereas    market    brain    safely    stroke    lost    fda    toxic    validating    nanoconstructs    productivity    rationally    profile    total    5m    investing    50    healthcare    therapeutic    efficacy    17m    revolutionize    moved    neurological    re    neurotoxicity    administration    safer    survivors    alleviate    interaction    molecule    commercial    fast    strokes    societal    circulation    therapies    suffering    statistics    combination    longer    direct    protocols    validated    25b    treatments    patent    cohort    approved    business    diagnostics    burden    economical    occlusion    disabilities    portfolio    thorough    reports    administered    fabrication    biodegradation    pharmaceutical    6m    faster    thrombectomy    patients    people    markets    tpa   

Project "RESOLVE" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA 

Organization address
address: VIA MOREGO 30
city: GENOVA
postcode: 16163
website: www.iit.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) coordinator 150˙000.00

Map

 Project objective

Acute ischemic strokes result from the occlusion of cerebral vessels by blood clots causing neurological complications, brain damage and death. Based on WHO reports, stroke affects 17M people per year worldwide, with 6M deaths and 5M survivors suffering long-lasting disabilities. Recent statistics estimate an EU direct healthcare cost for stroke of €20B and indirect costs, due to disabilities and lost productivity, of €25B. The two current treatments – thrombolysis and thrombectomy – come with limitations and considerable side effects. Thrombolysis can be safely administered only to a small cohort of patients (about 5%) whereas thrombectomy induces disabilities in 50% of the cases. Moved by the societal, economical, and emotional burden associated with stroke, this proposal aims at developing and validating more effective and less toxic therapies via the combination of the clinically approved molecule tPA and rationally-designed, discoidal polymeric nanoconstructs (DPNs). As compared to tPA, the proposed thrombolytic nano-agents (tPA-DPNs) are expected to provide faster blood clot dissolution; safer administration profile; longer blood circulation and stability. On the technical side, tPA-DPNs will be re-designed to improve their biodegradation and excretion profiles; validated in FDA-recognized stroke models for neurotoxicity and therapeutic efficacy. On the commercial side, a patent portfolio covering the fabrication and utilization of tPA-DPNs will be secured, together with thorough market and business analyses. This will facilitate the interaction with pharmaceutical companies that are investing in the fast growing markets of high-tech drug delivery systems and stroke diagnostics and therapies. tPA-DPNs are expected to alleviate the economic burden on healthcare systems, increase the total sale of thrombolytic agents, revolutionize the medical protocols for stroke management, and diminish the societal and emotional impact of stroke.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESOLVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESOLVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

INFANT MEMORIES (2020)

Dissecting hippocampal circuits for the encoding of early-life memories

Read More  

DYNAPOL (2019)

Modeling approaches toward bioinspired dynamic materials

Read More  

FuncMAB (2019)

High-throughput single-cell phenotypic analysis of functional antibody repertoires

Read More